p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice - Wikidata - wikimedia - TriplyDB

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

http://www.wikidata.org/entity/Q28364478

about

NADPH oxidase in stroke and cerebrovascular disease Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system Chronic granulomatous disease Protein Oxidation in Aging: Does It Play a Role in Aging Progression?Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis NADPH oxidases: key modulators in aging and age-related cardiovascular diseases?3-nitrotyrosine modified proteins in atherosclerosis Out, damned dot: studies of the NADPH oxidase in atherosclerosis Reactive oxygen species in inflammation and tissue injury The SecA2 secretion factor of Mycobacterium tuberculosis promotes growth in macrophages and inhibits the host immune response HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production Airway smooth muscle relaxation is impaired in mice lacking the p47phox subunit of NAD(P)H oxidase Nrf2 and the promotion of atherosclerosis: lessons to be learned p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases Nuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart.Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice.A copy number variation in human NCF1 and its pseudogenes Oxidative risk for atherothrombotic cardiovascular disease.NADPH oxidases in vascular pathology.Nox2 mediates high fat high sucrose diet-induced nitric oxide dysfunction and inflammation in aortic smooth muscle cells Oxidative stress in the pathology and treatment of systemic lupus erythematosus Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries Role of vascular oxidative stress in obesity and metabolic syndrome.Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo.Crossroads between peripheral atherosclerosis, western-type diet and skeletal muscle pathophysiology: emphasis on apolipoprotein E deficiency and peripheral arterial disease.The presence of p47phox in liver parenchymal cells is a key mediator in the pathogenesis of alcoholic liver steatosis NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis.Deletion of metallothionein exacerbates intermittent hypoxia-induced oxidative and inflammatory injury in aorta.Antagonistic effect of TNF-alpha and insulin on uncoupling protein 2 (UCP-2) expression and vascular damage.Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase.Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosis Assessment of atherosclerosis in chronic granulomatous disease The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling.Role for Nox1 NADPH oxidase in atherosclerosis

P2860

Q26859140-65647231-1360-4357-91BF-059C74E72E19 Q26861119-62A55624-5D11-492C-8A44-73A1B1401229 Q26991619-44C33395-3868-4D0F-A59C-27F0341C8D2F Q27009322-2D70B4FC-38BB-4815-BB68-807642E15CD4 Q27021668-3B1E649E-076A-4563-A008-5458A88BC3C2 Q27315993-CDC4B065-B2A3-423F-8047-FF2B94D238D9 Q28072348-1C305B25-4784-4077-A5B3-53E492647B02 Q28083260-A75AEBFA-1CF1-40E0-AD9C-0EA7496A5C8F Q28364447-D86BE140-C7B1-47AD-8DDF-C5BA372A57EA Q28396273-4E3F6F6A-87C2-4701-B75B-2B8130701DF6 Q28487596-F5622B31-137F-4D85-B4EC-D3BD0C1F2046 Q28580308-44170A85-5E4E-48AE-BB6C-CAD3AFAEC1D5 Q28588703-42A7E6C9-5E7E-49D2-8AF8-4A916BA12E0C Q29541148-E398B6D1-A43C-4AA9-975A-5D81FBAD849E Q30157297-FBDB6CAE-19F7-40A0-BE45-C0ACB20B8828 Q30275291-F938CED0-D7E5-4D16-99FD-1714B77C4BFF Q33386022-267C8EAA-1F44-41BF-9201-8EFD96C4431E Q33533669-EC10A645-8748-46B0-B5A4-C6AB55EB983D Q33554184-D84ED887-E456-4845-AE8C-2186DA27B58D Q33632089-093B067B-9508-4F53-A542-89BA546EF961 Q33680596-F5ED0CD2-A1EC-4ED8-BD63-830208E66A20 Q33715508-5C7CA138-BDD3-4569-A25C-4DACE2B1CFDC Q33737346-9379D72B-BF1C-4931-BEFB-D6923E3CD3B2 Q33744942-2532BEAE-EFED-4737-A4A7-EAEE0D16C31C Q33789308-D96DC48F-B1DF-44A2-A192-BB3B76585A74 Q33869754-66D74886-62AC-4698-BC7A-BEC47A192EF5 Q33885504-0FB8D0EF-EFFC-4DE8-8985-BD01046E76F4 Q33997351-C47055D5-BE66-4B72-935F-A728BFD3F1C2 Q34074465-8EB4FA05-3ACC-4C42-B3B3-DC550255BD10 Q34074823-C89422CE-7BD0-4FB3-80A5-CAF865FBC7B3 Q34079885-7AFD2E30-5519-476F-AE2A-1DC67851CB54 Q34109196-18D62BF7-506E-4FC6-9BDD-50D17171A9DC Q34217495-0CCF0B9A-A176-4078-B87C-16684A7565C0 Q34239967-B358FA39-6D6B-4B5E-9454-EA5FE62F1067 Q34406716-6C4935E1-6402-4658-B6B1-833C77C0EC38 Q34650014-65534683-B84A-428A-BCC3-DA933075A7F1 Q34860956-6C82973D-00DB-4CB0-8DBD-9AC4C53BBB05 Q34978758-4CC5C7A4-2B94-4212-B719-2A867D584AE3 Q34979530-882B2D57-4967-41F9-ABD8-384C47A7854B Q35032392-81147FE9-CDDE-4D63-9653-DD606D566BAD

P2860

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

http://www.wikidata.org/entity/Q28364478

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@ast

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@en

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@nl

type

label

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@ast

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@en

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@nl

prefLabel

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@ast

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@en

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@nl

P1433

Q28364478-5F8CFB21-2E0F-466D-BD27-8A357075BCC3

P1476

Q28364478-1DC04311-A249-42FF-B7B8-F959E9B27B7B

P2093

Q28364478-02A2EF76-5D18-49EA-BB4D-84BCDB18C8EC

Q28364478-5D812BA7-3215-4052-A27B-CC76139A9895

Q28364478-5E73089E-92CC-4E48-BEA9-8194E755E22B

Q28364478-B01492A3-9FB3-474E-B3EF-4B46241E6409

Q28364478-D1225352-AE48-437A-9B43-07D05C52D7C9

Q28364478-DBE43904-652E-4151-AB05-2B8DE9CF4D2F

Q28364478-E80867C7-44A1-4E96-81C4-F1E462C212C2

P2860

Q28364478-00CC0D40-9FFF-480B-A35B-4C89A478173E

Q28364478-0984A12E-BB27-450C-A869-24C516E2E391

Q28364478-10AE4B28-3A4B-4A4B-83E7-B7454E737CFF

Q28364478-431510D7-54D7-4320-A826-19BA7D4FFD5F

Q28364478-7286B0B1-6DF6-42FE-BC3B-A1B5A26A58D2

Q28364478-7D021AE1-218A-41CD-AC88-8E67E1DFCB12

Q28364478-7D7FEE41-FC56-4E8F-85CE-D220BC169DF6

Q28364478-845F756D-C570-463D-A094-3D2B0864C1C9

Q28364478-95BA8CDF-19D8-40D9-A9A0-8D9F2985AFAC

Q28364478-99DB31A9-3B10-4F2F-99EA-42134319A256

P304

Q28364478-BE0CB7EE-7DF3-4380-A6C2-B29F03A87E43

P31

Q28364478-AD716549-97B2-4312-9EA7-876DD73E4887

P3181

Q28364478-8C355ECC-023A-478B-BB19-5E4B3253BC8B

P356

Q28364478-7FEA1B9D-54AF-427A-95FE-EE032047FB3E

Q28364478-CD8B779B-C6B6-4977-942F-C5CE8D5B8067

P407

Q28364478-D31DA0FD-B590-4993-A185-8740E29B66B3

P433

Q28364478-95A78B98-9E0F-407C-BC05-3027B5517B3B

P478

Q28364478-C2CA613A-D1C6-42D7-B1FA-B071CC64576A

P577

Q28364478-6FC45AB5-3F7C-4B9B-94F6-FF9B7121B7F7

P698

Q28364478-FED14B01-1101-4C31-BF0E-AECF7D733F7F

P921

Q28364478-7355172E-6946-49AA-A37C-E77F3535D0A8

P932

Q28364478-BAAF8BBD-1461-4C20-8A52-CD9A2B8EF6DE

P3181

P356

P1433

Journal of Clinical Investigation

P1476

p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice

@en

P2093

C Patterson

http://www.w3.org/2001/XMLSchema#string

E T Yeh

http://www.w3.org/2001/XMLSchema#string

M S Runge

http://www.w3.org/2001/XMLSchema#string

M van der Merwe

http://www.w3.org/2001/XMLSchema#string

P A Barry-Lane

http://www.w3.org/2001/XMLSchema#string

S M Holland

http://www.w3.org/2001/XMLSchema#string

Z Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Cell transformation by the superoxide-generating oxidase Mox1

Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease

Cytochrome b-558 alpha-subunit cloning and expression in rat aortic smooth muscle cells

Vascular effects following homozygous disruption of p47(phox) : An essential component of NADPH oxidase

p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells

Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle

Cell cycle versus density dependence of smooth muscle alpha actin expression in cultured rat aortic smooth muscle cells.

Redox signals that regulate the vascular response to injury.

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.

Hypercholesterolemia increases endothelial superoxide anion production

P304

1513-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

813835

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI11927

http://www.w3.org/2001/XMLSchema#string

10.1172/JCI200111927

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11714743

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

209414

http://www.w3.org/2001/XMLSchema#string